|
|
|
|
Serum Cholesterol and CHD
|
|
|
|
Lipoprotein classes and atherosclerosis
|
|
|
|
ROLE OF LDL IN CAUSING ATHEROSCLEROSIS
|
|
|
|
Statin Trials: LDL-C Levels vs Events
|
|
|
|
PROVE-IT:Changes From Baseline LDL-C
|
|
|
|
PROVE-IT: All-cause Mortality
|
|
|
|
TNT-Study Design
|
|
|
|
TNT-Changes in LDL-C By Treatment Group
|
|
|
|
TNT-Primary Efficacy Outcome Measure
|
|
|
|
TNT-Stroke
|
|
|
|
TNT-Primary Endpoint
|
|
|
|
TNT-Safety
|
|
|
|
TNT-Major CVE
|
|
|
|
TNT-Major CVE
|
|
|
|
TNT-All-cause mortality
|
|
|
|
TNT-Non-CV mortality
|
|
|
|
Cardiovascular Mortality in Secondary Prevention Studies
|
|
|
|
Non-cardiovascular Mortality in Secondary Prevention Studies
|
|
|
|
Diabetic Subgroup in TNT
|
|
|
|
Metabolic Syndrome Subgroup in TNT
|
|
|
|
IDEAL - Protocol
|
|
|
|
IDEAL: Effect of Treatment On LDL-C
|
|
|
|
IDEAL: Composite End Points
|
|
|
|
MIRACL Study Design
|
|
|
|
MIRACL Results
|
|
|
|
MIRACL Results
|
|
|
|
MIRACL Results
|
|
|
|
MIRACL Conclusion
|
|
|
|
ARMYDA trial: Study design
|
|
|
|
Primary end point
|
|
|
|
ARMYDA trial: Primary end point
|
|
|
|
ARMYDA trial: Conclusions
|
|
|
|
All statin clinical outcome trials
|
|
|
|
Effects of aggressive vs moderate therapy with statins
|
|
|
|
All statin clinical outcome trials
|
|
|
|
Aggressive vs moderate statin therapy: effects in diabetes
|
|
|
|
All statin clinical outcome trials: effects of baseline LDL-C
|
|
|
|
Aggressive vs moderate therapy: effects of baseline LDL-C
|
|
|
|
All statin clinical outcome trials: effects of gender
|
|
|
|
All clinical outcome trials: effects of duration of treatment
|
|
|
|
|
All statin clinical outcome trials: effects on Cancer
|
|
Managing the late consequences of CHD (PPTX 1.3MB)
Share this page with your colleagues and friends: